Autonomix Medical, a development-stage medical device company focused on sensing and treating peripheral nervous system disorders, reported QQ3 2025 results with no revenue disclosed in the quarter. The company posted an operating loss of $2.747 million driven by a total operating expense base of $2.747 million, with R&D of $1.044 million and G&A of $1.703 million. EBITDA was negative at $2.62 million and net income was -$2.712 million for the quarter, with basic and diluted EPS at -$1.46. QoQ improvements in operating income (3.14%) and net income (3.38%) combined with a yoy improvement in earnings per share (EPS) of -758.82% reflect some cost containment and cadence improvements in spending, even as revenue remains absent. The company augmented its liquidity via equity financing, issuing common stock of $10.025 million, which increased cash and cash equivalents to $11.823 million at period end from $5.155 million at the start, providing a runway into the next 12–18 months for R&D and clinical milestones. On the balance sheet, Autonomix shows a robust current ratio (5.31x) and a net cash position (net debt of -$10.69 million), with no long-term debt, underscoring financial flexibility to support product development. The core investment question remains whether Autonomix can convert its platform into a revenue-generating product through partnerships, regulatory clearance, or licensing deals; until then, the stock remains a high-risk, high-uncertainty investment profile sensitive to clinical and regulatory progress.